Drug Profile
BIM 28011
Latest Information Update: 04 May 2007
Price :
$50
*
At a glance
- Originator Biomeasure Inc
- Class Growth factors; Hormones
- Mechanism of Action Growth hormone releasing factor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Dwarfism; Skin ulcer; Turner's syndrome
Most Recent Events
- 12 Sep 2000 No-Development-Reported for Skin ulcer in France (Unknown route)
- 12 Sep 2000 No-Development-Reported for Turner's syndrome in France (Unknown route)
- 29 Apr 1997 Phase-I clinical trials for Turner's syndrome in France (Unknown route)